

UCB – our commitment to epilepsy



Atsumi,
living with epilepsy



Our heritage

UCB has a rich heritage in epilepsy, with over 20 years of experience in the research and development (R&D) of novel antiepileptic drugs (AEDs). Every day, thousands of people use AEDs from our portfolio to help control their seizures.

We are building on our proven track record with an innovative R&D pipeline for the future. As a company with a long-term commitment to epilepsy research, our goal is to address unmet medical needs and to deliver solutions that improve patients' lives.

Our scientists are proud to contribute to advances in the understanding of epilepsy and its treatment. We look forward to a time when no one's life is limited by epilepsy.

We are Inspired by patients

Everything we do starts with a simple question:
how will this make a difference to the lives of people with severe diseases?

We are responding to the valuable insights we have gained from healthcare professionals, patients and their families so that we can make a meaningful difference. We have a patient-centric approach that goes beyond our medicines.

At UCB, we are inspired by patients and driven by science in our commitment to support patients with epilepsy.

We are Driven by science

Scientific excellence is fundamental to all of our R&D projects aimed at identifying new epilepsy therapies.

We focus on addressing key unmet needs, notably drug-resistant epilepsy and disease modification. We leverage advances in our knowledge of the complex cellular and molecular changes that take place in epilepsy to search for novel targets for new therapies that can address the pathophysiological basis of drug resistance and the disease itself.

We contribute to cutting-edge research leading to the identification of novel AED targets,¹ and validation of mechanisms that have potential for future therapeutic interventions for epilepsy.²

Our scientists are an integral part of the epilepsy community and contribute to discussions and debate on future avenues for discovery and development of new therapies that can progress epilepsy treatment.^{3,4}

We believe that sharing knowledge and expertise is essential for the rapid advancement of scientific understanding in epilepsy. To this end we partner and create super-networks with world-leading scientists and clinicians in academic institutions, pharmaceutical companies and other organisations who share our goals.

If you have molecular targets or inventions that you believe may advance care of epilepsy patients, please contact us directly at epilepsydiscovery@ucb.com. We look forward to talking with you and to sharing our insights, motivation and commitment.

References

1. Kaminski R.M., Gillard M. & Klitgaard H. Targeting SV2A for Discovery of Antiepileptic Drugs. Jasper's Basic Mechanisms of The Epilepsies. 4th Edition, 2012:1-12
2. Mazzuferi M., Kumar G., van Eyll J., Danis B., Foerch P. & Kaminski R.M. Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy. *Ann Neurol*. 2013 74(4):560-8
3. Simonata M., Löscher W., Cole A.J., Dudek F.E., Engel J. Jr., Kaminski R.M., Loeb J.A., Sharfman H., Staley K.J., Velisek L. & Klitgaard H. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. *Epilepsia*. 2012 53(11):1860-1867
4. Löscher W., Klitgaard H., Twyman R.E. & Schmidt D. New avenues for anti-epileptic drug discovery and development. *Nat Rev Drug Discov*. 2013 12(10):757-76